| 1.79 -0.06 (-3.24%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.66 | 1-year : | 3.09 |
| Resists | First : | 2.27 | Second : | 2.65 |
| Pivot price | 1.97 |
|||
| Supports | First : | 1.67 | Second : | 1.39 |
| MAs | MA(5) : | 1.83  |
MA(20) : | 2.04 |
| MA(100) : | 1.85 |
MA(250) : | 3.4 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.9 |
D(3) : | 24.8 |
| RSI | RSI(14): 38.4 |
|||
| 52-week | High : | 9.36 | Low : | 1.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LUNG ] has closed above bottom band by 23.0%. Bollinger Bands are 11.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.87 - 1.88 | 1.88 - 1.89 |
| Low: | 1.76 - 1.77 | 1.77 - 1.78 |
| Close: | 1.77 - 1.79 | 1.79 - 1.81 |
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Thu, 22 Jan 2026
Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Sat, 10 Jan 2026
Does Pulmonx (NASDAQ:LUNG) Have A Healthy Balance Sheet? - Sahm
Wed, 31 Dec 2025
Pulmonx Corporation (NASDAQ:LUNG) Short Interest Update - MarketBeat
Fri, 05 Dec 2025
Improved Revenues Required Before Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Jump Looks Justified - simplywall.st
Thu, 13 Nov 2025
D. Boral Capital Maintains Pulmonx (LUNG) Buy Recommendation - Nasdaq
Wed, 12 Nov 2025
Pulmonx Corporation (LUNG) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 41 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 78.4 (%) |
| Shares Short | 2,960 (K) |
| Shares Short P.Month | 2,530 (K) |
| EPS | -1.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.46 |
| Profit Margin | -62 % |
| Operating Margin | -67 % |
| Return on Assets (ttm) | -23.4 % |
| Return on Equity (ttm) | -73.8 % |
| Qtrly Rev. Growth | 5.5 % |
| Gross Profit (p.s.) | 1.62 |
| Sales Per Share | 2.22 |
| EBITDA (p.s.) | -1.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -1.27 |
| PEG Ratio | 0 |
| Price to Book value | 1.22 |
| Price to Sales | 0.8 |
| Price to Cash Flow | -2.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|